Long-Term Disease Control with Triapine-Based Radiochemotherapy for Patients with Stage IB2â€“IIIB Cervical Cancer by Charles A. Kunos & Tracy M. Sherertz
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CLINICALTRIAL ARTICLE
published: 24 July 2014
doi: 10.3389/fonc.2014.00184
Long-term disease control with triapine-based
radiochemotherapy for patients with stage IB2–IIIB cervical
cancer
Charles A. Kunos1* andTracy M. Sherertz 2
1 Department of Radiation Oncology, Summa Cancer Institute, Summa Health System, Akron, OH, USA
2 Department of Radiation Oncology, CASE Comprehensive Cancer Center, University Hospitals Case Medical Center, CaseWestern Reserve University School of
Medicine, Cleveland, OH, USA
Edited by:
Adam Paul Dicker, Thomas Jefferson
University, USA
Reviewed by:
Loren K. Mell, University of California
San Diego, USA
Aradhana Kaushal, National Cancer
Institute, USA
*Correspondence:
Charles A. Kunos, Department of
Radiation Oncology, Summa Cancer
Institute, G-90 161 North Forge
Street, Akron, OH 44304, USA
e-mail: kunosc@summahealth.org
Background: National Cancer Institute phase I #7336 and phase II #8327 clinical tri-
als explored the safety and efficacy of triapine (NSC #663249) added to cisplatin
radiochemotherapy in untreated patients with advanced-stage cervical cancer. Triapine
inhibits ribonucleotide reductase, the rate-limiting enzyme responsible for DNA-building
deoxyribonucleotides, and thereby, enhances radiochemosensitivity by prolonging DNA
repair time. Here, we report 3-year efficacy endpoints of pelvic locoregional relapse rate,
disease-free, and overall survivals.
Methods: Eligible patients with bulky IB–IIIB cervical cancer underwent three-times
weekly triapine (25 or 50 mg/m2), once-weekly cisplatin (40 mg/m2), and conventional daily
pelvic radiation followed by brachytherapy. A cumulative incidence method estimated pelvic
locoregional relapse rates. Disease-free survival was measured from radiochemotherapy
start date to the date of first relapse or cancer-related death. Overall survival was mea-
sured from radiochemotherapy start date to the date of any-cause death.The Kaplan–Meier
method estimated survivals.
Findings: Between 2006 and 2011, 24 untreated patients with cervical cancer met crite-
ria for reporting in this study. A median 3.4 years of follow-up time (range, 0.3–7.6 years)
has been observed. All had squamous cancers and the majority had either node-positive
stage IB–IIA (33%) or stage IIIB (42%) disease.The 3-year pelvic locoregional relapse rate,
disease-free survival, and overall survival were 4% [95% confidence interval (CI), 0–20%],
80% (95% CI: 71–89%), and 82% (95% CI: 74–90%), respectively.
Interpretation:Triapine radiochemotherapy was safe, active, and effective in patients with
untreated advanced-stage cervical cancer, worthy of randomized clinical trial study.
Keywords: triapine, cervical cancer, ribonucleotide reductase, radiation, cisplatin
INTRODUCTION
Incomplete radiochemotherapeutic treatment responses and
poorer cancer-related survivals occur if human papilloma virus
(HPV) and abnormal p53 signaling overactivates ribonucleotide
reductase in cancers of the uterine cervix (1–8). Human cer-
vical cancer cells overproduce de novo deoxyribonucleotides
(the building blocks of DNA), overhaul radiochemotherapy-
induced DNA damage more easily than other cancer cells, and
outlive cytotoxic radiochemotherapy exposures (5–8). Pharma-
cological blockade of ribonucleotide reductase lowers enzyme
catalytic activity, lengthens repair time of radiochemotherapy-
induced DNA damage, and elicits cancer cell death (5–8).
Enhanced cell lethality after ribonucleotide reductase inhi-
bition may take advantage of a time-critical unmet high
de novo deoxyribonucleotide demand during low de novo
deoxyribonucleotide supply (9). In previously conducted clinical
trials in untreated patients with advanced-stage cervical can-
cer, inhibitors of ribonucleotide reductase (e.g., hydroxyurea,
5-fluorouracil, and gemcitabine) have improved radiochemother-
apy efficacy (10–12). Another ribonucleotide reductase inhibitor,
triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone,
NSC #663249), has further boosted radiochemotherapeutic activ-
ity and efficacy in untreated patients with advanced-stage cervical
cancer (1, 2).
Overall, two important anticancer strategies have demonstrated
positive clinical outcomes in cervical cancer management: (a)
ribonucleotide reductase inhibition (1, 2), and (b) angiogenesis
inhibition (13, 14). This study of triapine radiochemotherapy pro-
tocols #7336 and #8327 was undertaken to report long-term clin-
ical outcomes and toxicity in selected previously untreated stage
IB2–IIIB cervical cancer patients nearly matching the Radiation
Therapy Oncology Group protocol #0417 cohort (13).
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METHODS
PATIENT ELIGIBILITY
For the triapine dose-finding phase I protocol #7336, eligible
patients had any histologically confirmed primary or recurrent
pelvic gynecologic malignancy not amenable to curative surgery.
For the triapine efficacy phase II protocol #8327, eligible patients
had squamous carcinoma, adenocarcinoma, or adenosquamous
carcinoma staged IB2–IVB of the uterine cervix or staged II–IV
of the vagina. Prior reports list detailed eligibility criteria (1, 2).
Herein, we exclusively report on those enrolled patients with Inter-
national Federation of Gynecologists and Obstetricians (FIGO)
stage II or IIIB disease, or node-positive FIGO stage IB2 whose
tumor size exceeded 5 cm (Figure 1; Table 1). All patients pro-
vided written informed consent. University Hospitals of Cleveland
and Case Western Reserve University (Cleveland, OH, USA) insti-
tutional review board approvals were granted for these clinical
trials. The Case Comprehensive Cancer Center of University Hos-
pitals of Cleveland and Case Western Reserve University provided
oversight for the data and safety monitoring plans.
RADIATION, CISPLATIN CHEMOTHERAPY, AND TRIAPINE TREATMENT
The details of dose-escalation and protocol therapy have been out-
lined previously (1, 2). Briefly, patients underwent three-times
weekly triapine [25 or 50 mg/m2 (1 h after radiation on days 1, 3,
and 5)] and once-weekly cisplatin [40 mg/m2 (prior to radiation
on day 2)] chemotherapy during daily four-field pelvic radiation
therapy (days 1 through 5). This schedule was repeated for five
FIGURE 1 | STROBE diagram for progress through stages of analysis.
STROBE, strengthening the reporting of observational studies in
epidemiology.
consecutive weeks (median 45 Gy). An anteroposterior parame-
trial boost with central pelvic shielding (median 9 Gy) was given
during week six, with any missed triapine doses allowed to be made
up during this boost. Intracavitary low-dose-rate brachytherapy
(median 40 Gy) brought the median point A dose to 85 Gy. No
adjuvant therapy was administered in these trials.
PATIENT ASSESSMENTS AND FOLLOW-UP
Patients had physical examinations and hematologic, hepatic,
and renal function blood testing and baseline computed tomog-
raphy (CT) or 2-[18F]fluoro-2-deoxy-d-glucose positron emis-
sion tomography scans (FDG PET/CT) within 28 days before the
start of radiochemotherapy. Physical examinations, adverse event
assessments (National Cancer Institute Common Terminology
Criteria for Adverse Events, version 3.0), and blood work were
repeated weekly. Posttherapy physical examinations and adverse
event assessments were required at 1 month and at 3 months after
completing all radiation therapy. Patients were followed gener-
ally every 3 months thereafter by one of the treating physicians.
Three-month FDG PET/CT scans were mandatory on the phase
II protocol #8327 and optional on the phase I protocol #7336.
Table 1 | Pretherapy patient and tumor characteristics (n=24).
Age (years)
Median 57
Range 33–68
Race
Black or African American 9 (38%)
White 15 (62%)
Ethnicity
Hispanic or Latino 2 (8%)
Not Hispanic or Latino 22 (92%)
Performance status
0 23 (96%)
1 1 (4%)
Histology
Squamous 24 (100%)
Adenocarcinoma 0 (0%)
Adenosquamous 0 (0%)
Histologic grade
G1: well differentiated 0 (0%)
G2: moderately differentiated 10 (42%)
G3: poorly differentiated 14 (58%)
Lymph node status
Positive 15 (63%)
Negative 9 (37%)
FIGO stage
IB2 6 (25%)
IIA 6 (25%)
IIB 2 (8%)
IIIA 0 (0%)
IIIB 10 (42%)
FIGO, international federation of gynecology and obstetrics.
Frontiers in Oncology | Radiation Oncology July 2014 | Volume 4 | Article 184 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kunos and Sherertz Triapine radiochemotherapy in cervical cancer
STATISTICAL METHODS
For this study, a pelvic locoregional relapse was defined as any
disease occurring within the pelvic radiation treatment field.
Extrapelvic distant disease relapse was defined as any new dis-
ease occurring outside of the radiation treatment field, inclusive
of para-aortic lymph node relapses. Pathologic confirmation of
relapse was not required. The rates of pelvic locoregional relapse
were calculated as a proportion and with the 95% confidence inter-
val (CI) determined with no continuity correction. Disease-free
survival events were defined as cancer-related death, locoregional
relapse, and extrapelvic relapse. Disease-free survival was mea-
sured from the start date of radiochemotherapy through the date
of first relapse or cancer-related death. Overall survival events
were deaths from any cause. Overall survival was measured from
radiochemotherapy start date through the date of death. Disease-
free and overall survival were calculated by the method of Kaplan
and Meier (15).
Toxicity endpoints were protocol-defined and scored accord-
ing to National Cancer Institute Common Terminology Criteria
for Adverse Events, version 3.0 (1, 2). Table 2 identifies protocol-
defined adverse events happening during therapy or within the
first 30 days posttherapy, and late adverse events occurring greater
than 30 days posttherapy.
RESULTS
PATIENTS
Phase I accrual to protocol #7336 occurred between May, 2006
and August, 2008. Phase II accrual to protocol #8327 transpired
between August, 2009, and November, 2011. Thirty-seven patients
were recruited to these two protocols from a single institution;
33 patients had squamous, adenocarcinoma, or adenosquamous
cancers of the uterine cervix of which 24 comprise this analysis
(Figure 1). Of the 13 patients excluded from this analysis, 1 patient
had stage IV uterine stromal sarcoma; 3 patients had vaginal can-
cer; 1 patient did not receive any protocol therapy; 1 patient had a
Table 2 | Protocol-defined triapine-attributed treatment adverse
events occurring at any time (n=24).
Acutea Lateb
Grade Grade
Category 3 4 3 4
Methemoglobinemia 0 0 0 0
Blood/bone marrow 2 0 0 0
Cardiovascular (general) 0 0 0 0
Gastrointestinal 0 0 1 0
Neurology 1 0 0 0
Renal (electrolyte) 1 2 0 0
Genitourinary 0 0 2 0
Worst non-hematologic 2 (8%) 2 (8%) 3 (13%) 0 (0%)
Worst overall 4 (17%) 2 (8%) 3 (13%) 0 (0%)
aOccurring on-treatment or within 30 days of any protocol treatment.
bOccurring >30 days after any protocol treatment.
pretherapy Zubrod performance status of 2; 1 patient had clinical
stage IIIB but radiographic stage IVB disease and died from an
iatrogenic Mallory–Weiss tear prior to brachytherapy; 2 patients
had stage IB2 node negative cervical cancer; 1 patient had stage
IVA cervical cancer; and 3 patients had clinical stage IVB cervi-
cal cancer. Pretherapy demographic and tumor characteristics for
the remaining 24 patients are listed in Table 1. Median follow-
up time was 3.4 years (range, 0.3–7.6 years). Median follow-up
among survivors was 3.8 years (range, 2.2–7.6 years). For the 24
patients reported herein, the median age was 57 years (range, 33–
68 years). The majority of the 24 patients had a pretherapy Zubrod
performance status of 0 (96%) and either node-positive stage IB–
IIA (n= 8, 33%) or stage IIIB (n= 10, 42%) disease. Although
these protocols included non-squamous cervical cancers, all 24
patients under study here had squamous cell cancers of the uterine
cervix. Fifteen (63%) had HPV subtype-16 and two (8%) had HPV
subtype-18. Seven tumors lacked (n= 5) or had unknown (n= 2)
HPV status by polymerase chain reaction–restriction fragment
length polymorphism.
ADVERSE EVENTS
Adverse events attributable to triapine administration or bio-
logic effect were low in these 24 patients (Table 2). Symptomatic
methemoglobinemia [i.e., methemoglobin concentration >20%
associated with dyspnea (1, 2)] did not occur in patients in
either protocol. Attributable grade 3 or 4 toxicity occurred on-
treatment or within 30 days of any protocol therapy in six patients
(25%). Attributable late >30-day posttherapy toxicity included
two (8%) incidences of grade 3 vaginitis and one (4%) incidence
of enterovaginal fistula. No triapine radiochemotherapy treatment
administration-related deaths took place.
TREATMENT COMPLIANCE
Compliance with clinical trial protocol-specified radiation and
chemotherapy administration was considered satisfactory. Three
National Cancer Institute-monitored audits confirmed data time-
liness and quality. A total of 342 (95%) of an expected 360 triapine
infusions occurred in the 24 patients studied here; there were no
triapine infusion-related adverse events.
EFFICACY
The 3-year pelvic locoregional relapse rate, disease-free survival,
and overall survival were 4% (95% CI: 0–20%), 80% (95% CI:
71–89%), and 82% (95% CI: 74–90%), respectively. Figure 2 plots
disease-free survival and overall survival curves. Nineteen (79%)
patients were without treatment failure at the time of last follow-
up. Among women in this particular cohort, a single right pelvic
sidewall relapse was detected at 8 months after the start of triap-
ine radiochemotherapy. In this patient, a 3-month FDG PET/CT
suggested an incomplete pelvic lymph node metabolic response
(2). At surgery conducted to palliate non-treatment-related pain,
a site of viable extranodal disease was removed surgically from
the right pelvic sidewall. Four extrapelvic relapses (i.e., outside the
radiation portal) have been recorded: two (8%) para-aortic lymph
node relapses; one (4%) abdominal wall relapse; and one (4%)
left supraclavicular lymph node relapse. Five (20%) deaths have
occurred. Two (8%) of the deaths were attributed to cancer-related
factors.
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A B
FIGURE 2 | Kaplan–Meier survival curves for disease-free survival (A) and overall survival (B).
DISCUSSION
Triapine added to cisplatin radiochemotherapy resulted in a
low treatment-related adverse event rate and produced a 3-year
disease-free survival rate of 80% (95% CI: 71–89%). These two
important clinical trials demonstrate how the supply and demand
economics of deoxyribonucleotides affect the degree to which
cervical cancers respond to conventional treatment. The major-
ity of cervical cancers have (1) HPVs that hijack ribonucleotide
reductase to mint deoxyribonucleotides for replication of viral
DNA, or (2) mutations in p53 that abrogate cell cycle restric-
tion checkpoints, free-up ribonucleotide reductase to increase
deoxyribonucleotide payout, and replicate DNA unchecked (9).
As a consequence of either biologic phenomenon, ribonucleotide
reductase subunits M2 and M2b are abundant in cervical can-
cer cells (3, 4). In this biologic state, ribonucleotide reductase
M2 and M2b subunits saturate its catalytic M1 subunit (3, 4),
which leads to overproduction of deoxyribonucleotides (5, 6).
Because cervical cancers are rich in active ribonucleotide reduc-
tase, which can facilitate DNA damage repair (3, 4), patients with
(over)active ribonucleotide reductase might have a less than ideal
radiochemotherapy treatment response. And yet when ribonu-
cleotide reductase activity is blocked, radiochemotherapy-induced
DNA damage persists, cancer cell death occurs, and cervical can-
cer disease becomes better controlled. Perhaps these concepts are
best demonstrated by the 4% rate of pelvic locoregional treatment
failure among previously untreated patients enrolled on these two
radiochemotherapy trials using triapine to inhibit cervical cancer
cell ribonucleotide reductase. Because of these intriguing findings,
a National Cancer Institute Cancer Therapy Evaluation Program
randomized phase II trial currently tests triapine radiochemother-
apy versus cisplatin radiochemotherapy in untreated patients with
locally advanced-stage cervical cancer (NCT01835171).
The antitumor consequence of ribonucleotide reductase inhi-
bition has not been the only advancement in cervical cancer
treatment. Angiogenesis inhibition has emerged as an effective
alternative anticancer treatment strategy for patients with can-
cers of the uterine cervix and may serve to frame the triap-
ine radiochemotherapy results reported herein. Inactivation of
angiogenesis effectors reduces small blood vessel growth, blocks
new blood vessel formation, and restores tumor blood nutri-
ent and oxygen supply so that treatments such as chemotherapy
and radiation are more deadly to cancer cells (16, 17). Gyneco-
logic Oncology Group protocol #227C studied single-agent beva-
cizumab (15 mg/kg every 21 days) as an angiogenesis inhibitor in
women with recurrent or metastatic cervical cancer and found
a 24% rate of disease-free survival at 6 months (18). Phase III
testing involved adding bevacizumab (15 mg/kg every 21 days)
to cisplatin–paclitaxel or cisplatin–topotecan chemotherapy in
patients with metastatic, persistent, or recurrent cervical cancer on
Gynecologic Oncology Group protocol #240 (14). Bevacizumab
was administered until disease progression or manifestation of
unacceptable toxicity. On this trial, a noteworthy 3.7-month
improvement in median overall survival (17 vs. 13.3 months) was
observed. Also, the Radiation Therapy Oncology Group embarked
upon protocol #0417 to evaluate the addition of three bevacizumab
doses (10 mg/kg) to weekly cisplatin radiochemotherapy in 49
patients with bulky stage IB2–IIIB cervical cancer (13). No main-
tenance bevacizumab was administered. The trial showed a 3-year
overall survival of 81% (95% CI: 67–90%), disease-free survival of
69% (95% CI: 54–80%), and cumulative incidence of locoregional
relapse of 23% (95% CI: 11–35%). The bevacizumab and cisplatin
radiochemotherapy grade 3 and grade 4 worst overall toxicity rates
were 27 and 10%, respectively.
Because of the exciting clinical outcomes for these two
ribonucleotide reductase inhibition clinical trials, a randomized
phase II trial of cisplatin radiochemotherapy alone or with co-
administered triapine has been put forward for consideration in
the National Cancer Institute National Clinical Trials Network
program.
RESEARCH IN CONTEXT
Systematic review
Our manuscript reports new 3-year safety and efficacy data
from clinical trials conducted with triapine radiochemotherapy
in untreated patients with advanced-stage IB2–IIIB cancers of the
uterine cervix. We searched PubMed with the terms “triapine,”
“radiation,” “cervical cancer,” and “clinical trial” for publications
between January 1, 1999, and May 1, 2014. Only the original single
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institution phase I (1) and phase II (2) trials were found – with
neither study providing more than 18-month clinical outcome
data. We broadened our publication search to include “beva-
cizumab,” given a publication discussing improved survival with
bevacizumab in patients with advanced cervical cancer (14). These
three bevacizumab clinical trials were selected to frame the con-
text of our new long-term triapine radiochemotherapy clinical
trial data (13, 14, 18).
Interpretation
Three-year clinical trial outcomes after three-times weekly triapine
added to cisplatin radiochemotherapy in patients with untreated
locally advanced-stage cervical cancer demonstrate efficacy results
that warrant further clinical trial evaluation. A randomized phase
II clinical trial currently recruits untreated patients with stage IB–
IVA cancers of the uterine cervix to cisplatin radiochemotherapy
with or without triapine (NCT01835171).
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